2021
COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients
Stewart M, Rodriguez-Watson C, Albayrak A, Asubonteng J, Belli A, Brown T, Cho K, Das R, Eldridge E, Gatto N, Gelman A, Gerlovin H, Goldberg SL, Hansen E, Hirsch J, Ho YL, Ip A, Izano M, Jones J, Justice AC, Klesh R, Kuranz S, Lam C, Mao Q, Mataraso S, Mera R, Posner DC, Rassen JA, Siefkas A, Schrag A, Tourassi G, Weckstein A, Wolf F, Bhat A, Winckler S, Sigal EV, Allen J. COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. PLOS ONE 2021, 16: e0248128. PMID: 33730088, PMCID: PMC7968637, DOI: 10.1371/journal.pone.0248128.Peer-Reviewed Original ResearchConceptsHospitalized COVID-19 patientsCOVID-19 patientsUse of hydroxychloroquineElectronic health recordsAdverse eventsTreatment groupsCOVID-19Administration of hydroxychloroquineReagan-Udall FoundationProportional hazards modelHealth systems researchHospitalized patientsElevated riskPropensity score methodsHazards modelHydroxychloroquinePatientsSignificant global threatPharmaceutical interventionsAzithromycinHealth recordsMortalityCOVID-19 pandemicCancer researchTreatment
2020
Frequency and Duration of Incarceration and Mortality Among US Veterans With and Without HIV.
Hawks LC, McGinnis KA, Howell BA, Khan MR, Edelman EJ, Justice AC, Wang EA. Frequency and Duration of Incarceration and Mortality Among US Veterans With and Without HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 84: 220-227. PMID: 32049771, PMCID: PMC7228828, DOI: 10.1097/qai.0000000000002325.Peer-Reviewed Original ResearchConceptsRisk of mortalityAdjusted hazard ratioCohort studyHIV statusVeterans Aging Cohort StudyCox proportional hazards modelTransitional health careProspective cohort studyAging Cohort StudyConfidence intervalsProportional hazards modelDose-response fashionFrequency of incarcerationDuration of incarcerationIncarceration exposureHIV careHazard ratioPrimary exposureUS veteransLeading causeHigh riskIncrease riskHazards modelCumulative durationPWH
2016
Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men
Justice AC, McGinnis KA, Tate JP, Braithwaite RS, Bryant KJ, Cook RL, Edelman EJ, Fiellin LE, Freiberg MS, Gordon AJ, Kraemer KL, Marshall BD, Williams EC, Fiellin DA. Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men. Drug And Alcohol Dependence 2016, 161: 95-103. PMID: 26861883, PMCID: PMC4792710, DOI: 10.1016/j.drugalcdep.2016.01.017.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyRisk of mortalityAUDIT-C scoresUninfected individualsPhysiologic injuryAlcohol exposureUndetectable HIV-1 RNACox proportional hazards modelAlcohol useVACS Index scoreHepatitis C infectionAging Cohort StudyHIV-1 RNAProportional hazards modelAlcohol consumption limitsLow alcohol exposureAlcohol-related harmRace/ethnicityAntiretroviral therapyC infectionUninfected menCohort studyHIV statusHazards modelIndex score
2015
Alcohol-Related Diagnoses and All-Cause Hospitalization Among HIV-Infected and Uninfected Patients: A Longitudinal Analysis of United States Veterans from 1997 to 2011
Rentsch C, Tate JP, Akgün KM, Crystal S, Wang KH, Ryan Greysen S, Wang EA, Bryant KJ, Fiellin DA, Justice AC, Rimland D. Alcohol-Related Diagnoses and All-Cause Hospitalization Among HIV-Infected and Uninfected Patients: A Longitudinal Analysis of United States Veterans from 1997 to 2011. AIDS And Behavior 2015, 20: 555-564. PMID: 25711299, PMCID: PMC4550577, DOI: 10.1007/s10461-015-1025-y.Peer-Reviewed Original ResearchConceptsAlcohol-related diagnosesHospitalization ratesUnited States veteransUninfected patientsCause hospitalizationHIV infectionStates veteransUninfected individualsMultivariable Cox proportional hazards modelsCox proportional hazards modelOverall hospitalization rateProportional hazards modelCancer admissionsAntiretroviral therapyMultivariable adjustmentHIV serostatusComorbidity variablesHospitalization trendsRelative riskHigh riskHazards modelHIVHospitalizationDisease categoriesPatients
2014
Comparison of Risk and Age at Diagnosis of Myocardial Infarction, End-Stage Renal Disease, and Non-AIDS-Defining Cancer in HIV-Infected Versus Uninfected Adults
Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, Rimland D, Rodriguez-Barradas MC, Dubrow R, Park LS, Skanderson M, Shiels MS, Gange SJ, Gebo KA, Justice AC. Comparison of Risk and Age at Diagnosis of Myocardial Infarction, End-Stage Renal Disease, and Non-AIDS-Defining Cancer in HIV-Infected Versus Uninfected Adults. Clinical Infectious Diseases 2014, 60: 627-638. PMID: 25362204, PMCID: PMC4318916, DOI: 10.1093/cid/ciu869.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseMyocardial infarctionUninfected adultsAge-associated eventsRenal diseaseHIV statusIncident diagnosisMean ageVeterans Aging Cohort StudyGreater riskCox proportional hazards modelAging Cohort StudyHuman immunodeficiency virusProportional hazards modelNon-AIDSUninfected veteransCohort studyMultivariate linear regression modelMedian ageComparison of risksImmunodeficiency virusAge-associated diseasesImportant confoundersHigh riskHazards modelThe VACS Index Accurately Predicts Mortality and Treatment Response among Multi-Drug Resistant HIV Infected Patients Participating in the Options in Management with Antiretrovirals (OPTIMA) Study
Brown ST, Tate JP, Kyriakides TC, Kirkwood KA, Holodniy M, Goulet JL, Angus BJ, Cameron DW, Justice AC, . The VACS Index Accurately Predicts Mortality and Treatment Response among Multi-Drug Resistant HIV Infected Patients Participating in the Options in Management with Antiretrovirals (OPTIMA) Study. PLOS ONE 2014, 9: e92606. PMID: 24667813, PMCID: PMC3965438, DOI: 10.1371/journal.pone.0092606.Peer-Reviewed Original ResearchConceptsVACS IndexCombination antiretroviral therapyNet reclassification improvementHIV biomarkersCause mortalityC-statisticTreatment interventionsMulti-drug resistant HIVHarrel's c-statisticsRespective hazard ratiosKaplan-Meier estimatesProportional hazards modelImproved scoresAntiretroviral studiesAntiretroviral therapyHazard ratioResistant HIVReclassification improvementRestricted IndexTreatment responseStudy interventionRisk scoreHazards modelVAC indexMortality
2004
Disease progression in HIV-infected patients treated with stavudine vs. zidovudine
Justice AC, Stein DS, Fusco GP, Sherrill BH, Fusco JS, Danehower SC, Becker SL, Hansen NI, Graham NM, Team T. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine. Journal Of Clinical Epidemiology 2004, 57: 89-97. PMID: 15019015, DOI: 10.1016/s0895-4356(03)00245-2.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveDatabases, FactualDisease ProgressionDisease-Free SurvivalFollow-Up StudiesHIV InfectionsHIV Wasting SyndromeHumansProportional Hazards ModelsProspective StudiesReverse Transcriptase InhibitorsStavudineZidovudineConceptsCells/microLDisease progressionLandmark analysisCox proportional hazards modelEvent-free survivalHIV-1 patientsHIV-1 RNAProportional hazards modelPrevious AIDSStavudine treatmentCD4 countHIV infectionInhibitor useCombination therapyUnadjusted analysesObservational studyHIV-1U.S. cohortHazards modelPatientsZidovudineStavudineNew casesNRTIsProgression